Leerink Partners Lowers Insulet (NASDAQ:PODD) Price Target to $360.00

Insulet (NASDAQ:PODD) had its price objective cut by research analysts at Leerink Partners from $386.00 to $360.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Leerink Partners’ price target would suggest a potential upside of 48.83% from the company’s previous close.

Several other equities analysts have also commented on the stock. TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price on the stock. in a report on Monday, January 26th. UBS Group reissued a “buy” rating on shares of Insulet in a research note on Thursday, December 18th. Sanford C. Bernstein lowered their price target on shares of Insulet from $410.00 to $380.00 and set an “outperform” rating for the company in a report on Friday, January 9th. Jefferies Financial Group raised their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Royal Bank Of Canada boosted their price target on Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Twenty research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $354.57.

Insulet Stock Down 2.9%

Shares of NASDAQ PODD opened at $241.89 on Thursday. The stock has a market capitalization of $17.03 billion, a PE ratio of 69.11, a P/E/G ratio of 1.55 and a beta of 1.41. Insulet has a one year low of $230.05 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.18. The business’s fifty day moving average price is $272.44 and its 200-day moving average price is $304.79.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The firm had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. During the same period in the previous year, the business earned $1.15 EPS. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities research analysts anticipate that Insulet will post 3.92 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet during the 4th quarter valued at about $26,000. Elyxium Wealth LLC bought a new stake in Insulet during the 4th quarter valued at about $28,000. DV Equities LLC purchased a new position in Insulet in the fourth quarter worth about $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of Insulet in the fourth quarter worth approximately $29,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported a strong Q4: revenue and EPS beats, margin expansion, record Omnipod growth and a bullish 2026 outlook; management also expanded the share‑repurchase program — these operational wins drove the initial post‑earnings rally. Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
• Positive Sentiment: Street reaction includes buy/overweight/outperform reiterations (BTIG reiterated Buy) and headlines noting a gap‑up after the earnings beat, which supported intraday upside earlier this week. BTIG Research Reiterates “Buy” Rating for Insulet Insulet Shares Gap Up Following Earnings Beat
• Neutral Sentiment: Reported short‑interest data is effectively zero/erroneous (0 shares), so there’s no clear short‑squeeze dynamic in play based on the available figures.
• Negative Sentiment: Multiple firms trimmed price targets this week (Raymond James to $355, Citigroup to $345, JPMorgan to $340, Leerink to $360). Although these firms mostly kept Buy/Outperform ratings, the lower targets remove some upside expectations and likely contributed to today’s pullback. Raymond James Adjusts Insulet Price Target Benzinga coverage of analyst target changes

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.